Clobetasol propionate is a highly active corticosteroid with topical anti-inflammatory activity. The major effect of clobetasol propionate on skin is a non-specific anti-inflammatory response, partially due to vasoconstriction and decrease in collagen synthesis.


Clobetasol Propionate BP 0.05% w/w.

Credavate should be used with the following indications:

  • Psoriasis (excluding widespread plaque psoriasis);
  • Eczema (in refractory form);
  • Lichen ruber planus;
  • Discoid lupus erythematosus;
  • Other skin diseases that are resistant to less active glucocorticoid therapy;
  • Skin disease resistant to less active GCS treatment, for topical use;

For topical use only.

Apply sparingly to the affected area once or twice daily until improvement occurs. As with other highly active topical steroid preparations, therapy should be discontinued when control is achieved. In the more responsive conditions, this may be within a few days. If no improvement is seen within two to four weeks, reassessment of the diagnosis, or referral, may be necessary.

Repeated short courses of Credavate may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used. In very resistant lesions, especially where there is hyperkeratosis, the anti-inflammatory effect of Credavate can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response. Thereafter, improvement can usually be maintained by application without occlusion.